Handok (Chairman & CEO Young-jin Kim, Vice President Jin-ki Paik) and Sugentech (CEO Mi-jin Sohn) signed a domestic sales agreement for allergy diagnosis products on June 30, 2021.

Sugentech is a company specializing in in-vitro diagnostic products using immunochemical technology based on a convergence of bio-, nano-, and information technologies. It develops and manufactures rapid detection kits, such as for Covid-19 and tuberculosis, and testing kits and analysis devices for allergies, autoimmune disease, female hormones, and cardiovascular diseases, among others. In 2020, Sugentech was the first company in Korea to acquire Emergency Use Authorization from the US Food and Drug Administration for its rapid detection kits for Covid-19 antibodies.

With this agreement, Handok will be in charge of domestic marketing and sales for Sugentech’s S-Blot3, a multiplex immunoblot automation device and SGTi-Allergy Screen, a diagnostic reagent for allergies. S-Blot3 is the world’s first device integrating reagent pretreatment and analysis. It can simultaneously diagnose reactions to more than 100 different allergens, including food, plants, and pollen, with only a small amount of blood. SGTi-Allergy Screen was Korea’s first allergy diagnostic product approved based on the Act on In Vitro Diagnostic Medical Devices enacted in 2019.